/6b20244e147454e8f086f35159086be4/n/dr-antonio-giordano)
Dr. Antonio Giordano is an Italian-American pathologist and geneticist, best known for his discovery of Rb2/p130, a tumor suppressor gene. Dr. Giordano is the president, founder and chairman of the board of the Sbarro Health Research Organization (SHRO), a nonprofit organization committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses, and to foster the training of young doctors in a spirit of professionalism and humanism.
Dr. Giordano is also the founder and director of the SHRO supported Sbarro Institute for Cancer Research and Molecular Medicine, as well as the Center for Biotechnology, which are both located in Temple University's College of Science and Technology. Dr. Giordano is also a 'Chiara fama' professor of pathology in the Department of Medicine, Surgery, and Neuroscience at the University of Siena, Italy where the Temple Summer in Siena Biomedical Research program is based.
Dr. Giordano earned his MD from the University of Naples in 1986, and he specialized in Pathology at the University of Trieste, earning his Ph.D in Pathology, summa cum laude.
/b2c0520e019ba7fbed0613a68f63e4c2/n/breast-cancer-in-the-post-genomic-era)
/f87ae66aa0cdb63dd7f127a346136ff1/n/cell-cycle-inhibitors-in-cancer-therapy-current-strategies)
/778827343af0b2ebbf705434bc5ba70d/n/molecular-pathology-of-gynecologic-cancer)
